Publication:
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations.

Simple item page
dc.contributor.authorLopez, Aurelio
dc.contributor.authorMateos, Maria-Victoria
dc.contributor.authorOriol, Albert
dc.contributor.authorValero, Marta
dc.contributor.authorMartinez, Joaquin
dc.contributor.authorLorenzo, Jose Ignacio
dc.contributor.authorPerez, Montserrat
dc.contributor.authorMartinez, Rafael
dc.contributor.authorde Paz, Raquel
dc.contributor.authorGranell, Miguel
dc.contributor.authorde Arriba, Felipe
dc.contributor.authorBlanchard, M Jesus
dc.contributor.authorPenalver, Francisco-Javier
dc.contributor.authorBello, Jose Luis
dc.contributor.authorMartin, Maria Luisa
dc.contributor.authorBargay Lleonart, Joan
dc.contributor.authorBlade, Joan
dc.contributor.authorLahuerta, Juan Jose
dc.contributor.authorSan Miguel, Jesus F
dc.contributor.authorde la Rubia Comos, Javier
dc.date.accessioned2024-07-04T12:54:47Z
dc.date.available2024-07-04T12:54:47Z
dc.date.issued2015
dc.description.abstractWe report the characteristics of relapse, treatment response, and outcomes of 145 elderly patients with multiple myeloma in first relapse after front-line treatment with VMP or VTP. Reappearance of CRAB symptoms (113 patients) and more aggressive forms of disease (32 patients) were the most common patterns of relapse. After second-line therapy, 75 (51.7%) patients achieved at partial response and 16 (11%) complete response (CR). Overall survival was longer among patients receiving VMP as front-line induction (21.4 vs. 14.4 months, P=0.037), in patients achieving CR (28.3 vs. 14.8 months; P=0.04), and in patients without aggressive relapse (28.6 vs. 7.6 months; P=0.0007).en
dc.format.number2es_ES
dc.format.page64-9es_ES
dc.format.volume4es_ES
dc.identifier.citationLopez A, Mateos MV, Oriol A, Valero M, Martinez J, Lorenzo JI, et al. Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations.. Leuk Res Rep. 2015;4(2):64-9.en
dc.identifier.doi10.1016/j.lrr.2015.09.002
dc.identifier.issn2213-0489
dc.identifier.journalLeukemia Research Reportses_ES
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/17426
dc.identifier.pubmedID26500850es_ES
dc.identifier.puiL606143667
dc.identifier.scopus2-s2.0-84942514302
dc.identifier.urihttp://hdl.handle.net/20.500.12105/20083
dc.language.isoengen
dc.relation.publisherversionhttps://dx.doi.org/10.1016/j.lrr.2015.09.002en
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectElderly patientsen
dc.subjectPatterns of relapseen
dc.subjectRelapsed myelomaen
dc.titlePatterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations.en
dc.typeresearch articleen
dspace.entity.typePublication

Files

Collections

IdisBa - Instituto de Investigación Sanitaria Illes Balears (Baleares)
IDIBAPS - Instituto de Investigaciones Biomédicas August Pi i Sunyer (Cataluña)